3 results
Approved WMOCompleted
The purpose of this study is to investigate the effectiveness and safety of riociguat (BAY 63-2521) in patients with diffuse cutaneous systemic sclerosis.
Approved WMOCompleted
The aim of this trial is to test in a first clinical study the above mentioned hypothesis that BAY63-2521 can at least partially correct deltaF508-CFTR function. Therefore, we plan to include patients with Cystic Fibrosis, who are homozygous for the…
Approved WMOWill not start
The primary objective of this study is to assess tolerance and efficacy of 12 weeks BP1.3656 (30 µg or 60 µg OD versus placebo) to reduce alcohol consumption in alcohol dependent patients.